HIMS & HERS HEALTH INC (HIMS)

December 27th Options Now Available For Hims & Hers Health (HIMS)

Why HIMS & HERS HEALTH INC (NYSE:HIMS) qualifies as a high growth stock.

Is HIMS & HERS HEALTH INC (NYSE:HIMS) suited for growth investing?

Noteworthy Wednesday Option Activity: HIMS, TRIP, AMBC

Missed Out on Eli Lilly? Buy This Amazing Growth Stock Instead

The company expects to enjoy many GLP-1 tailwinds in 2025.

IBD 50's No. 2 Stock, Hims & Hers, Smashes Estimates On 'Robust' Obesity Trajectory

Hims stock jumped late Monday after the online pharmacy beat expectations.

Hims & Hers Health, Inc. Reports Third Quarter 2024 Financial Results

Notable Wednesday Option Activity: HIMS, UAL, AMGN

Could This Magnificent Pharma Stock 10x in the Next 5 Years?

Disrupting pharmacies is just the start for Hims & Hers.

Telehealth Firms See Ozempic Copycats Sparking Employer Interest in Covering Weight-Loss Drugs

Hims & Hers and other telehealth providers say employers that balked at pricey brand-name shots are investigating cheaper off-brand alternatives.

How Compounded Treatments Are Helping Hims & Hers Customers Meet Their Weight Loss Goals

Hims Says Weight-Loss Shot ‘Just as Safe’ as Ozempic and Wegovy

Hims & Hers Health Inc. said an analysis of more than 10,000 patients taking a copycat version of Novo Nordisk A/S’s Ozempic and Wegovy showed the shot was a safe and effective way to shed pounds.

Hims & Hers Stock Dropped: Here's What You Need to Know

The GLP-1 drama continues at Hims & Hers.

Hims & Hers names Dr. Jessica Shepherd as Chief Medical Officer of Hers

Why Hims & Hers' Incredible Growth Will Continue

GLP-1s get all the attention, but Hims & Hers' core business is where the rocket growth is.

Hims & Hers Shares Have Rallied 22% This Week. Why That Move Is Now At Risk.

Hims & Hers has enjoyed a rally on an FDA decision regarding Eli Lilly's tirzepatide.

Hims & Hers Health Larger Than S&P 500 Component Deckers Outdoor

Noteworthy Tuesday Option Activity: HIMS, R, BBY

Hims & Hers to Announce Third Quarter 2024 Financial Results on November 4, 2024

Hims & Hers Health Pops After FDA Allows Compounded Copies Of Eli Lilly's Obesity Drug

An industry group sued the FDA, claiming tirzepatide remains in shortage.